Clinical Trials
55 trialsDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Columbia University
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
R-PMDT Regimen in Newly Diagnosed PCNSL
Institute of Hematology & Blood Diseases Hospital, China
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
M.D. Anderson Cancer Center
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
GLOHRT-01
Huazhong University of Science and Technology
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Chinese PLA General Hospital
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
VIWA-1
University of Ulm
REFRACT
University of Birmingham
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
M.D. Anderson Cancer Center
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
ACCELERATE
Center for International Blood and Marrow Transplant Research
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Beth Israel Deaconess Medical Center
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
Odronextamab in Low Tumor Volume Advanced FL
Beth Israel Deaconess Medical Center
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
MZL-IIT-O
Institute of Hematology & Blood Diseases Hospital, China
BRAZAN
Dana-Farber Cancer Institute
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Venetoclax and Decitabine in R/R T-ALL
Seoul National University Hospital
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
M.D. Anderson Cancer Center
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
M.D. Anderson Cancer Center
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Asan Medical Center
IMCL-2023
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
FIL_Tisle-HL
Fondazione Italiana Linfomi - ETS
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
MALMBA
Seoul National University Hospital
LATE-R-GEL-23
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Benefit VA
VA Office of Research and Development
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Columbia University
EpLCART
Peter MacCallum Cancer Centre, Australia
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Case Comprehensive Cancer Center
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
Second Affiliated Hospital of Soochow University
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Immune Oncology Research Institute
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
LORELY
Istituto Clinico Humanitas